OBJECTIVES: Currently two modes of administration are available for biologic therapies used to treat immunology conditions: intravenous infusion (IV) and subcutaneous injection (SQ).  This study explores patient perceptions of IV biologic therapy for treatment of immunology conditions among patients of different race/ethnicity. METHODS: Semi-structured telephone interviews were conducted with 405 immunology patients currently treated with IV biologic therapy.  Patients identified preference for IV or SQ and reasons for preference.  Patient perceptions were assessed by agreement (6=agree or 7=strongly agree on a 7-point scale) with a series of statements about mode of administration.  RESULTS: The sample included 83.5% (n=338) Caucasian/White, 7.9% (n=32) African-American/Black, and 5.2% (n=21) Hispanic.  While all patients preferred IV to SQ, African-American/Black patients had a stronger preference than Caucasian/White patients (96.9% vs. 79.9%, p<0.050).  Of those preferring IV, a greater proportion of African-American/Black patients reported not wanting to give self-injections or not liking needles as a reason for IV preference (71.0% vs. 40.0% for Caucasian/White patients and 38.9% for Hispanic patients, p<0.050 for both).    A significantly larger proportion of African-American/Black patients agreed with the following statements than Caucasian/White patients (p<0.05 for all): IV medications are stronger than non-IV medications (50.0% vs. 31.7%); an IV infusion would be less painful than injections (37.5% vs. 23.4%); I don’t like needles and therefore don’t like the idea of having to give myself injections (46.9% vs. 24.0%); I would be concerned about the risk of doing harm to myself if I had to give myself injections (40.6% vs. 16.3%); it is easier for me to schedule an appointment at an infusion center than to remember when to give myself injections (37.5% vs. 17.2%).  CONCLUSIONS: Patient perceptions of IV biologic therapy differ by race/ethnicity.  Coverage and access policies that limit availability of IV biologic therapy may disproportionately affect racial/ethnic minorities.